Eisai Company, Limited

Toshiharu Ohgoh

Tadashi Sato

Satoru Tanaka

Tsuneo Wakabayashi

Issei Ohtsuka

Toshinobu Kunii

Kouichiro Ueda

Mayumi Kawase

Kengo Kagei

Isao Yamatsu

Yuichi Inai

Manabu Murakami

Hideki Ono

Shinya Abe

Takeshi Suzuki

Shizumasa Kijima

Kiyoshi Oketani

Hideaki Fujisaki

Ono Hideki

Novel hydantoin derivatives and salts thereof, the process for the preparation thereof, and medicines containing the same, wherein the hydantoin derivatives are represented by the general formula: ##STR1## wherein X.sub.1 and X.sub.2, which may be the same or different, mean independently hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; Y means oxygen atom or sulfur atom, R.sub.1 and R.sub.2, which may be the same or different, mean independently hydrogen atom, a lower alkyl group or phenyl group, or the both may form a ring with a carbon atom which is combined with them, excluding the case wherein both R.sub.1 and R.sub.2 are hydrogen atom at the same time, and n means an integer of 0 or 1. The novel hydantoin derivatives and salts thereof have excellent effects for the treatment of the complications of the diabetes mellitus.

Hydantoin derivatives and medicines containing the same

Hydantoin derivatives and salts thereof, the process for the preparation thereof, and medicines containing the same, wherein the hydantoin derivatives are represented by the general formula: ##STR1## wherein the substituents are defined hereinbelow. The hydantoin derivatives and salts thereof have excellent effects for the treamtment of the complications of the diabetes mellitus.

Hydantoin derivatives for treating complications of diabetes

Novel hydantoin derivatives and salts thereof, the process for the preparation thereof, and medicines containing the same, wherein the hydantoin derivatives are represented by the general formula: ##STR1## wherein X.sub.1 and X.sub.2, which may be the same or different, independently represent a hydrogen atom, a halogen atom, a lower alkyl group or a lower alkoxy group; Y represents an oxygen atom or sulfur atom, R.sub.1 and R.sub.2, which may be the same or different, independently represent a hydrogen atom, a lower alkyl group or phenyl group, or both may form a ring with carbon atoms, excluding the case wherein both R.sub.1 and R.sub.2 are hydrogen atom, and n represents 0 or 1. The novel hydantoin derivatives and salts thereof have excellent effects for the treatment of the complications of diabetes mellitus.

Treating complications of diabetes mellitus with hydantoin derivatives

6,10,14,18-Tetramethyl-5,9,13,17-nonadecatetraene-2-ols of the general formula: ##STR1##

6,10,14,18-Tetramethly-5,9,13,17-nonadecatetraene-2-ol

A therapeutic preparation having excellent effect for peptic ulcers with low toxicity which comprises aliphatic ketone derivative of the general formula: ##STR1## wherein  represents a saturated or unsaturated bond, R.sub.1 is hydrogen or a lower alkyl group, R.sub.2 is hydrogen atom, a lower alkyl group or a lower alkylcarbonyl group, R.sub.3 is an aliphatic hydrocarbon group of the general formula: ##STR2## WHEREIN L, M AND N ARE 0 OR 1, PROVIDED THAT L+M+N.gtoreq.2; AND A, B, C, D, E AND F ARE HYDROGEN ATOM, OR THEY MAY FORM A BOND OF A--B, C--D OR E--F, PROVIDED THAT IF THE BOND  IS A SATURATED BOND, THE A, B, C, D, E AND F REPRESENT ALL HYDROGEN ATOM.

Therapeutic preparations for peptic ulcers comprising aliphatic ketone

Growing community of inventors

Aichi, Japan

Toshiharu Ohgoh